TARS Q3 2023 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$1M79.9% margin

Operating Income

-$41M-2187.9% margin

Net Income

-$39M-2092.4% margin

EPS (Diluted)

$-1.28

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$37M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$268M

Total Liabilities

$55M

Stockholders' Equity

$214M

Cash & Equivalents

$227M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$1M	-$211,000	+808.1%
Operating Income	-$41M	-$23M	-78.7%
Net Income	-$39M	-$23M	-73.9%

Revenue Segments

Product

$2M88%

License And Collaboration

$218,00012%